Lv55
1129 积分 2023-03-30 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
2天前
已完结
Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus
3天前
已完结
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
3天前
已完结
Facts and Hopes of Chimeric Antigen Receptor-Redirected Natural Killer T cells
3天前
已完结
Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study
4天前
已完结
Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial
4天前
已完结
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
7天前
已完结
The race to reset autoimmune diseases
8天前
已完结
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
9天前
已完结
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
24天前
已完结
皖公网安备34019202002308
